Chemotherapy News and Research

Latest Chemotherapy News and Research

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive similar care despite differences in disease characteristics and outcomes.

12 Dec 2025

Tianjin grading system improves prognosis prediction in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic tools.

12 Dec 2025

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint blockades in solid cancers.

12 Dec 2025

Preoperative MRI offers no survival benefit for early-stage breast cancer patients

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional recurrence whether or not they underwent preoperative breast magnetic resonance imaging (MRI) in addition to diagnostic mammography to determine the extent of their cancer, according to results from the phase III Alliance A011104/ACRIN 6694 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025

Proton therapy improves survival in oropharyngeal cancer patients

A new study published today in The Lancet showed a significant survival benefit for patients with oropharyngeal cancers who were treated with proton therapy (IMPT) compared to those treated with traditional radiation therapy (IMRT).

11 Dec 2025

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025

Interventions to treat valvular heart disease in cancer patients significantly improve survival

Valvular heart disease, identified through cardiovascular imaging, is common in cancer patients. Interventions to treat valvular heart disease significantly improved survival.

11 Dec 2025

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Triaptosis could be a promising strategy in the fight against cancer

Cancer remains one of the most critical global public health challenges, exerting profound social, economic, and clinical burdens while limiting gains in human life expectancy.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Nanoflower-treated stem cells deliver healthier mitochondria to stressed cells

This study shows that vacancy-engineered MoS₂ nanoflowers drive mitochondrial biogenesis in human mesenchymal stem cells by activating SIRT1–PGC-1α signaling and reducing oxidative stress. These treated cells transfer more functional mitochondria to injured recipient cells, restoring energy metabolism and redox balance in multiple in vitro models.

9 Dec 2025

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood cancers, such as myeloma and lymphoma, as well as solid tumors.

9 Dec 2025

Trump’s idea for health accounts has been tried. Millions of patients have ended up in debt.

Sarah Monroe once had a relatively comfortable middle-class life. She and her family lived in a neatly landscaped neighborhood near Cleveland. They had a six-figure income and health insurance. Then, four years ago, when Monroe was pregnant with twin girls, something started to feel off.

9 Dec 2025

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Powerful prognostic marker could enable early identification of high-risk cancer patients

Aggressive T-cell lymphoma is a rare and devastating form of blood cancer with a very low five-year survival rate.

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

8 Dec 2025

Chemotherapy News and Research

Latest Chemotherapy News and Research

Early relapse predicts poor survival in mature nodal T-cell lymphoma

Tianjin grading system improves prognosis prediction in pancreatic cancer

AI-guided discovery of selective DGKα inhibitors to overcome checkpoint resistance in solid cancers

Preoperative MRI offers no survival benefit for early-stage breast cancer patients

Proton therapy improves survival in oropharyngeal cancer patients

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Interventions to treat valvular heart disease in cancer patients significantly improve survival

Antibody therapy clears residual multiple myeloma in early trial

AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Triaptosis could be a promising strategy in the fight against cancer

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Nanoflower-treated stem cells deliver healthier mitochondria to stressed cells

New antibody shows ability to overcome treatment resistance in blood cancers and solid tumors

Trump’s idea for health accounts has been tried. Millions of patients have ended up in debt.

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Powerful prognostic marker could enable early identification of high-risk cancer patients

Combination therapy may boost survival for people with aggressive lymphoma

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in